EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists

Trevor Sharp iD, Aurelija Ippolito

British Journal of Pharmacology · 2026-07 · 183 (14) · 3935-3949

DOI: 10.1111/bph.70050 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 23.05.2025. Verfasst von Trevor Sharp und 1 weiteren Autor:innen. Beteiligte Einrichtung: University Department of Pharmacology, Oxford, UK. Hauptthemen laut MEDLINE: Hallucinogens, Serotonin 5-HT2 Receptor Agonists, Receptor, Serotonin, 5-HT2A, Mental Disorders. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council MRC-DTP Industrial Studentship for Aurelija Ippolito, University of Oxford, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s. However, these drugs are now experiencing a renaissance in the field of psychiatry based on increasing evidence that they can produce long‐lasting improvements in health across a wide variety of mental illnesses, including major depression, addictions and anxiety disorders. These drugs interact with many different 5‐HT receptor subtypes but the powerful psychedelic experience, which (depending on set and setting) includes profound alterations in perception, mood and cognition, accompanied by vivid hallucinations, is now widely considered mediated by an agonist action at 5‐HT 2A receptors. However, the link between the psychedelic experience, 5‐HT 2A receptor agonism and therapeutic effects is currently uncertain. Indeed, recent research has revealed a new class of 5‐HT 2A receptor agonists which appear to retain the therapeutic potential of psychedelics drugs without inducing disorienting hallucinatory experiences. Biased signalling, partial agonism and non‐selectivity at the 5‐HT 2A receptor are amongst the possible explanations for the differential properties of these drugs, whereas increased neuroplasticity offers a likely account of their common therapeutic effects. This article explores the neuropsychopharmacological properties of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists in the context of their promise as novel drug treatments in psychiatry. LINKED ARTICLES This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensSerotonin 5-HT2 Receptor AgonistsReceptor, Serotonin, 5-HT2AMental DisordersHumansAnimals

Stichwörter der Autor:innen

5‐HT5‐HT2A receptorantidepressanthallucinogenspsychedelicsserotonin

Substanzen

HallucinogensSerotonin 5-HT2 Receptor AgonistsReceptor, Serotonin, 5-HT2A

Autor:innen und Institutionen

  • University Department of Pharmacology, Oxford, UK.

ORCID-Profile: Trevor Sharp

Förderung

  • Medical Research Council MRC-DTP Industrial Studentship for Aurelija Ippolito
  • University of Oxford
  • Medical Research Council

Zitieren

APA

Sharp, T., & Ippolito, A. (2026). Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists. British Journal of Pharmacology, 183(14), 3935-3949. https://doi.org/10.1111/bph.70050

Vancouver

Sharp T, Ippolito A. Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists. British Journal of Pharmacology. 2026;183(14):3935-3949. doi:10.1111/bph.70050

BibTeX
@article{Sharp2026,
  author = {Sharp, Trevor and Ippolito, Aurelija},
  title = {Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {14},
  pages = {3935--3949},
  doi = {10.1111/bph.70050}
}
Kostenlos starten →